iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. The company was incorporated in 2008 and is headquartered in San Diego, California. Show more
Location: 11750 Sorrento Valley Road, San Diego, CA, 92121, United States | Website: https://ibioinc.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
16.89M
52 Wk Range
$0.56 - $6.89
Previous Close
$0.86
Open
$0.86
Volume
329,643
Day Range
$0.83 - $0.86
Enterprise Value
11.32M
Cash
8.582M
Avg Qtr Burn
-3.826M
Insider Ownership
2.86%
Institutional Own.
16.45%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IBIO-610 Details Obesity | Phase 1 Initiation | |
IBIO-200/202 Details COVID-19 | Failed Discontinued |